Cagrilintide is Novo Nordisk's once-weekly amylin analog, not a GLP-1. On its own it cut body weight 6.0% to 10.8% vs 3.0% on placebo over 26 weeks.[3] It is not approved by itself; Novo filed CagriSema, its combination with semaglutide, with the FDA in December 2025 and expects a decision in the fourth quarter of 2026.[5][6]
Most of the attention in obesity pharmacology has fixed on one hormone pathway — GLP-1. Cagrilintide is the molecule that quietly makes the case for a different one. It is a long-acting analog of amylin, a gut-brain hormone with its own appetite-suppressing job, engineered by Novo Nordisk to be dosed once weekly. It is best known as one half of the combination CagriSema, but it has a standalone evidence base worth reading on its own terms — and understanding cagrilintide alone is the cleanest way to see what amylin agonism actually contributes.
What is cagrilintide? Amylin, not GLP-1
Amylin is a peptide hormone co-secreted with insulin from pancreatic β-cells after a meal. Its physiology is distinct from the incretin system: rather than amplifying insulin release the way GLP-1 does, amylin acts chiefly as a satiation signal — it slows gastric emptying, blunts the post-meal rise in glucagon, and signals fullness through receptors in the hindbrain.[1] In other words, amylin and GLP-1 both reduce how much you eat, but they get there through largely separate machinery. That separation is the entire pharmacological argument for developing an amylin drug at all. If a second, independent appetite brake exists, it can in principle be pulled on its own or stacked on top of GLP-1 — which is precisely the logic the field has pursued.
Why an analog, and why long-acting
Native human amylin is a poor drug. It aggregates, is unstable, and clears quickly, which is why the first clinical amylin agonist, pramlintide, had to be dosed multiple times a day at mealtimes. Cagrilintide was designed to fix that: it is a structurally modified, soluble amylin analog with a fatty-acid modification that extends its half-life enough for once-weekly subcutaneous dosing, matching the cadence of modern GLP-1 therapies.[2] This re-engineering is what turned amylin from a niche, inconvenient adjunct into a candidate weight-management agent in its own right. The development of long-acting amylin analogs like cagrilintide is, fairly read, the event that revived serious interest in the amylin pathway for obesity.[2]
What results did cagrilintide show on its own?
The pivotal standalone evidence is a multicenter, randomized, double-blind, placebo- and active-controlled Phase 2 dose-finding trial of once-weekly cagrilintide in adults with overweight or obesity but without type 2 diabetes.[3] Over 26 weeks in 906 randomized adults, cagrilintide produced dose-dependent weight loss of 6.0 to 10.8 percent, against 3.0 percent on placebo — a placebo-subtracted range of 3.0 to 7.8 percentage points (p < 0.001) — and notably, the top 4.5 mg dose also edged the liraglutide 3.0 mg active comparator, 10.8 percent versus 9.0 percent (difference 1.8 points, p = 0.03).[3] That is the headline that matters: amylin agonism alone, without any GLP-1 on board, is a genuine weight-management lever, not merely a helper molecule. The trial was a dose-finding study rather than a long, hard-outcome Phase 3, so the honest framing is proof-of-concept-grade efficacy — convincing for the mechanism, not yet a settled clinical verdict.
How it differs from the GLP-1 drugs people know
Three differences are worth keeping straight. First, target: cagrilintide acts on amylin (calcitonin-receptor/RAMP) signaling, not the GLP-1 receptor, so it is mechanistically a different class even though the clinical goal overlaps.[1] Second, effect size and maturity: the most potent GLP-1 and dual GLP-1/GIP agonists currently carry larger and far more extensively documented weight-loss and outcome data than cagrilintide monotherapy, whose standalone record is still mainly Phase 2. Third, tolerability character: amylin agonists share the gastrointestinal, dose-dependent side-effect tendency of the broader gut-hormone class, with nausea the common limiter as the dose escalates. The practical upshot is that cagrilintide is not a stronger or weaker version of a GLP-1 — it is a complementary tool that happens to chase the same outcome by a different route.
The “other half” of CagriSema
Cagrilintide’s highest-profile role is as the amylin component of CagriSema, the fixed-dose combination that pairs it with the GLP-1 agonist semaglutide in a single weekly injection. The rationale follows directly from the mechanism above: if amylin and GLP-1 suppress appetite through complementary pathways, combining them could add up to more than either alone. That hypothesis was supported early by a Phase 1b study showing the two peptides could be co-administered with a pharmacokinetic and tolerability profile compatible with a fixed-dose combination,[4] and it was then carried into the large REDEFINE Phase 3 program. We cover that combination, and the more nuanced-than-hyped results it produced, in our companion piece on CagriSema and the REDEFINE program. The key point for this page is the order of the logic: cagrilintide had to stand up as a credible weight-loss agent on its own first, which the Phase 2 monotherapy data did, before it earned its place as the amylin half of the combination.
When could cagrilintide be approved?
Cagrilintide occupies an unusual position. As a standalone agent it is still defined principally by Phase 2 monotherapy evidence: the Phase 3 REDEFINE 1 trial did include a cagrilintide-only arm (302 of 3,417 participants), but it was built to test the combination, which produced a 20.4% vs 3.0% weight loss against placebo at 68 weeks.[7] So cagrilintide is best described as an investigational amylin analog with strong proof-of-concept efficacy, not an established stand-alone therapy, and Novo has not filed it for approval on its own. Its route to market runs through the combination: on December 18, 2025, Novo Nordisk submitted a New Drug Application to the FDA for once-weekly CagriSema for weight management, based on REDEFINE 1 and REDEFINE 2.[5] In a September 30, 2026 release, Novo still described CagriSema as investigational and said it expects the FDA's decision in the fourth quarter of 2026.[6] Until that decision, neither cagrilintide nor CagriSema is approved in the US. More broadly, cagrilintide is the clearest current example of a wider trend: obesity drug development is expanding beyond GLP-1 monotherapy toward multi-hormone strategies, and the amylin pathway is one of the most credible additional levers in that expansion.[2] CagriSema pairs two molecules to reach both pathways; Novo is also testing whether one molecule can do it, in amycretin, a single-peptide GLP-1 and amylin co-agonist — an approach still at the Phase 1 stage, where the weight-loss numbers are early rather than settled.
The honest bottom line
Cagrilintide matters because it validates a second appetite pathway. It is a re-engineered, long-acting amylin analog that, dosed once weekly and entirely on its own, produced dose-dependent weight loss in a controlled Phase 2 trial and even beat a GLP-1 comparator at its higher doses.[3] That makes it a legitimate weight-management mechanism in its own right, not merely semaglutide’s sidekick. The fair caveats are that its standalone evidence is still proof-of-concept-grade rather than a mature outcomes program, that it carries the gut-hormone class’s gastrointestinal tolerability profile, and that most of its public story has been written as the amylin half of CagriSema. Read cleanly, cagrilintide is a promising, mechanistically distinct amylin analog — convincing on biology, still early on the standalone clinical record. Two newer selective amylin agonists, eloralintide and petrelintide, are now testing that same pathway with far larger weight-loss numbers; we cover them, and the incretin candidates competing with them, in the next wave of obesity drugs.